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A B S T R A C T
Obesity incidence has pandemic proportions and is expected to increase even further. Glucagon-like peptide-1
(GLP-1) based therapies are well-established pharmacological resources for obesity treatment. GLP-1 regulates
energy and glucose homeostasis, which are also crucial for spermatogenesis. Herein, we studied the GLP-1 effects
in human Sertoli cells (hSCs) metabolism and mitochondrial function. hSCs were cultured in absence or exposed
to increasing doses of GLP-1 mimicking physiological post-prandial (0.01 nM) levels or equivalent to pharma-
cological levels (1 and 100 nM) used for obesity treatment. We identified GLP-1 receptor in hSCs. Consumption/
production of extracellular metabolites were assessed, as well as protein levels or activities of glycolysis-related
enzymes and transporters. Mitochondrial membrane potential and oxidative damage were evaluated. Glucose
consumption decreased, while lactate production increased in hSCs exposed to 0.01 and 1 nM GLP-1. Though
lactate dehydrogenase (LDH) protein decreased after exposure to 100 nM GLP-1 its activity increased in hSCs
exposed to the same concentration of GLP-1. Mitochondrial membrane potential decreased in hSCs exposed to
100 nM of GLP-1, while formation of carbonyl groups was decreased in those cells. Those effects were followed
by an increase in p-mammalian target of rapamycin (mTOR) Ser(2448). Overall, the lowest concentrations of
GLP-1 increased the efficiency of glucose conversion to lactate, while GLP-1 concentration of 100 nM induces
mTOR phosphorylation, decreases mitochondrial membrane potential and oxidative damage. GLP-1 regulates
testicular energy homeostasis and pharmacological use of GLP-1 analogues could be valuable to counteract the
negative impact of obesity in male reproductive function.
1. Introduction
Obesity has emerged as a major healthcare problem increasing the
risk of cardiovascular diseases and decreases lifespan (Fontaine et al.,
2003). Reduced fertility is a silent obesity-related complication, which
among other co-morbidities is becoming a matter of concern (Alves
et al., 2016). Dysregulation in the hormonal control of energy home-
ostasis promoted by the balance between food intake and energy ex-
penditure has been hypothesized to interfere not only in body meta-
bolism, but also with fertility though the underlying mechanisms
remain unknown.
Glucagon like peptide-1 (GLP-1) is a 29-amino acid amidated
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peptide hormone, produced by posttranslational cleavage of the pro-
glucagon precursor protein (Bell et al., 1983). This peptide is mainly
produced by intestinal L-cells and secreted post-prandially (Guedes
et al., 2015). GLP-1 is known for its role in glucose homeostasis pre-
dominantly mediated by the incretin effect. It potentiates insulin se-
cretion after oral glucose ingestion, as compared to intra-venous glu-
cose administration. GLP-1 also acts in the central nervous system to
reduce the appetite and delays gastric emptying. Glucose equilibrium is
crucial for energy homeostasis and the proper functioning of physio-
logical functions, including male fertility. However, due to in vivo fast-
proteolytic digestion mainly by dipeptidyl peptidase 4 (DPP4) and renal
clearance, GLP-1 has a short half-life (Ruiz-Grande et al., 1993) that
limits the use of the native peptide for pharmacological purposes. Thus,
several GLP-1 analogues are available, being options for treatment of
diabetes and obesity, as these promote weight loss, while having a low
risk of causing hypoglycaemia (Crane and McGowan, 2016).
GLP-1 exerts its activity via GLP-1 receptor (GLP-1R), which belongs
to a G-protein coupled receptor family (Bullock et al., 1996). GLP-1R
expression within the male reproductive system has been detected in
mice Sertoli cells (SCs) (Zhang et al., 2015), evidencing that GLP-1
should have an impact on male fertility. In fact, GLP-1R knockout mice
have reduced seminal vesicle and gonadal weighs, despite depicting
normal testicular sex steroids levels and retaining fertility (MacLusky
et al., 2000).
While it is known that GLP-1 and its analogues are key regulators of
metabolism, the molecular means which by they impact cell metabo-
lism, remain unknown. It has been postulated that mitochondria are the
main metabolic targets for this hormone (for review Alves et al., 2016).
For instance, GLP-1 improves mitochondrial membrane potential
(Ogata et al., 2014) and also mitochondrial mass in a pancreatic cell
line (Kang et al., 2015). Indeed, both GLP-1 analogues and DPP4 in-
hibitors, which increase endogenous GLP-1 levels by preventing its
degradation, modulate mitochondrial structure and functioning (for
review Ranganath, 2008). These metabolic processes depend on sig-
nalling pathways network. The mammalian target of rapamycin
(mTOR) kinase emerged as pivotal for these processes (for review
Oliveira et al., 2017), controlling mitochondrial bioenergetics and
glucose metabolism. GLP-1 interferes with mTOR pathway (Park et al.,
2015) and recently it was suggested that mTOR has an essential role in
male reproduction (Jesus et al., 2017). In addition, mTOR controls
glucose consumption and redox balance of human SCs (hSCs) (Jesus
et al., 2016). The SCs are responsible for the nutritional support of
spermatogenesis and the major hormonal target inside the testis
(Martins et al., 2015; Martins et al., 2016). Herein, we studied the GLP-
1 effects on hSCs metabolism and mitochondrial function. We hy-
pothesized that GLP-1 could interfere in hSC function with potential
implications for the nutritional support of spermatogenesis.
2. Methods
2.1. Chemicals
All chemicals were obtained from Sigma-Aldrich (St. Louis, MO,
USA) unless specified otherwise.
2.2. Patient's selection and testicular tissue preparation
Testicular tissue was obtained from testicular biopsies (n=6) per-
formed to men with conserved spermatogenesis, suffering from aneja-
culation due to previous vasectomy or traumatic section of the vas
deferens, with the ultimate aim of recovering gametes for medically
assisted procreation. After informed written consent, hSCs were isolated
from the testicular tissue left in culture plate once gamete retrieval was
completed. Testicular biopsies and handling of testicular tissue was
done at the Centre for Reproductive Genetics Professor Alberto Barros
(Porto, Portugal) in accordance with the Guidelines of Local, National
and European Ethical Committees and performed in agreement with the
Declaration of Helsinki.
2.3. Sertoli cells culture
Human SCs were isolated following the protocol optimized by
Oliveira and collaborators (Oliveira et al., 2009). Anti-Mullerian hor-
mone and vimentin, were used, as specific protein markers, to assess the
purity of the hSCs cultures (Steger et al., 1996). Only cultures with a
purity above 95% were used, SC cultures purity was determined by
phase contrast microscopy using an ExtrAvidin Peroxidase Staining Kit.
To establish the various experimental groups, cells were washed
with PBS, and placed in culture serum-free medium (DMEM: Ham's F12,
pH 7.4) with insulin-transferrin‑sodium selenite medium (final con-
centration of 10mg/L; 5.5mg/L; 6.7 μg/L, respectively) to which GLP-1
(Bachem AG, Bubendorf, Switzerland) was added (or not). One group of
cells was not exposed to GLP-1 (0 nM) (no GLP-1) and three other
groups were treated with increasing concentrations of GLP-1 (0.01, 1
and 100 nM). The concentration of 0.01 nM was chosen taking into
consideration the postprandial GLP-1 levels found in healthy in-
dividuals (Vilsboll et al., 2001; Balestrieri et al., 2015). The other GLP-1
concentrations were chosen to mimic the highest plasmatic con-
centrations attained after administration of a GLP-1 analogue at the
maximum therapeutic dosage recommended for obese individuals
(3 mg/daily for liraglutide) either after a single administration (1 nM)
or at steady state after a daily administration for 5 weeks (100 nM)
(Elbrond et al., 2002; Jiang et al., 2011; Danne et al., 2017).
After 6 h of treatment, cell culture medium was also collected.
Afterwards, the cells were washed and exposed to GLP-1 for 6 h. We
chose this time period for the exposure of cells to GLP-1 based on GLP-1
half-life (Ruiz-Grande et al., 1993). The cells were then washed with
PBS and detached using a Trypsin-EDTA solution (0.05% / 0.02% (w/
v)), counted using a Neubauer chamber and collected for protein, DNA
and RNA extraction. Only groups with viability averaging 85–90%,
evaluated by Trypan Blue Exclusion test, were considered for analysis.
2.4. RNA and DNA extraction
Total RNA (RNAt) was extracted using the E.Z.N.A.® RNAt com-
mercial Kit (Omega Bio-Tek, Norcross, USA) and DNA was extracted
using the E.Z.N.A.® Tissue DNA Kit Commercial Kit (Omega Bio-Tek,
Norcross, USA), as indicated by the manufacturer. The amount of DNA
and RNA was determinated using a NanoDrop 1000 Spectrophotometer
(Thermo Fisher Scientific, Wilmington, USA). The 260/280 nm of the
samples were used to assess the purity of DNA and RNA. DNA presented
a ratio of ≈1.8 and RNA presented a ratio of ≈2 in the extracted
samples. To assess the integrity of RNA and DNA, an aliquot of each
sample was run on a denaturing agarose gel stained with GreenSafe
(NZYTech, Lisboa, Portugal).
2.5. cDNA synthesis and Reverse Transcriptase Polymerase Chain Reaction
(RT-PCR)
RNAt was reversely transcribed as previously described (Martins
et al., 2015). The resultant cDNA was used with exon-exon spanning
primer sets designed to amplify specific cDNA fragments (Table 1). PCR
was performed with a primer's optimal annealing temperature, using
standard methods (Martins et al., 2015) (Table 1). The samples were
visualized using the software Image Lab (BioRad, Hercules, CA, USA)
coupled to an image acquisition system BioRad FX-Pro-plus (BioRad,
Hemel Hempstead, UK). The product size was compared to a DNA
ladder (NZYTech, Lisboa, Portugal). Human heart and human liver
RNAt (AMS Biotechnology, Abingdon, UK) were used as positive con-
trol and cDNA-free sample was used as negative control.
The mRNA expression levels of GLP-1R were evaluated in the dif-
ferent experimental groups. qPCR experiments were carried out in
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triplicate, in a CFX 96 qPCR setup (BioRad, Hercules, CA, USA). The
efficiency of the amplification for all primers sets was determined by
using serial dilutions of cDNA (Martins et al., 2015). Amplification
conditions were followed as previously described (Martins et al., 2016).
β-2-microglobulin (β2M) transcript levels were used to normalize the
mRNA expression of the target genes. The target genes, sequences and
annealing temperatures of the primers are described in Table 1. Fol-
lowing the mathematical model proposed by Pfaffl in the formula:
2−ΔCt, the fold variation the target gene expression was calculated.
2.6. Determination of mtDNA copy number
A qPCR analysis was performed to study the mtDNA copy number as
described (Fuke et al., 2011) with small modifications. The efficiency of
the amplification was determined by serial dilutions of DNA, and the
amplification conditions used were as previously described (Alves et al.,
2014). The reaction mixture consisted in NZY qPCR Mix (NZYTech,
Lisboa, Portugal), primers (Table 1) and 20 ng of mtDNA. Each reaction
was carried out in an CFX 96 (Biorad, Hercules, USA). Ct value differ-
ences between NADH dehydrogenase subunit 1 (ND1) gene and nuclear
encoded beta-2-microglobulin (β2Mnc) gene were used to quantify
mtDNA copy number relative with the following model proposed by
Pfaffl: 2-ΔCt.
2.7. Cytotoxicity assay
A sulforhodamine B (SRB) colorimetric assay was performed to test
the cytotoxicity of GLP-1 to hSCs (Skehan et al., 1990). The cells were
seed and treated with the selected concentrations of GLP-1. After 6 h,
the assay was performed as previously described (Martins et al., 2015).
No cytotoxicity was observed for the GLP-1 concentrations used (data
not shown).
2.8. Western blot
Total proteins isolated from hSCs were extracted using the M-PER
Mammalian Protein Extraction Reagent (Thermo Scientific, Rockford,
USA). Western blot was performed as previously described (Alves et al.,
2014). The membranes were incubated overnight at 4 °C with primary
and secondary antibodies (Table 2). Mouse β-tubulin was used as pro-
tein loading control. ECF detection system was used and the membranes
were read in the BioRad FX-Pro-plus (BioRad, Hemel Hempstead, UK).
The densities from each band were quantified according to standard
methods using Image Lab (BioRad, Hemel Hempstead, UK). Whenever
possible the membranes were stripped with Restore Western Blot
Stripping Buffer (Thermo Scientific, Rockford, USA) following the
manufacturer's instructions, blocked and marked with other primary
and consequently secondary antibody.
2.9. Lactate dehydrogenase (LDH) activity
The commercial Pierce LDH Kit (Thermo Scientific, Rockford, USA)
was used to measure LDH activity. The obtained values of activity were
calculated using the molar absorptivity of formazan
(ε=19,900M−1.cm−1).
2.10. Measurement of oxidative damage
The oxidative damage to proteins and lipids was evaluated by Slot-
blot. We determined the protein carbonyl, nitro-tyrosine (NT) and 4-
hydroxynonenal (4-HNE) group levels as previously described (Martins
et al., 2015). The membranes were incubated with primary and sec-
ondary antibodies (Table 2). ECF detection system was used, the
membranes were read in the BioRad FX-Pro-plus and the densities from
each band were quantified using Image Lab (BioRad, Hemel Hemp-
stead, UK).
2.11. Glutathione content assay
Glutathione content of cells exposed to GLP-1 was performed using
the commercial kit to quantify total, oxidized and reduced glutathione
contents (Enzo Life Sciences, Lausen, Switzerland), according to the
manufactory instructions.
2.12. Mitochondrial membrane potential
The cation JC-1 dye (Molecular Probes, Eugene, OR, USA) was used
to evaluate mitochondrial membrane potential. Cells were exposed to
the chosen concentrations of GLP-1 for 6 h and mitochondrial mem-
brane potential determined as previously described (Martins et al.,
2016). Fluorescent intensity was measured using a Cytation 3 Imaging
Reader (BioTek Instruments, Winooski, USA). The ratio of the fluor-
escent intensity of JC-1 aggregates to monomers was used as an in-
dicator of mitochondria membrane potential.
2.13. Nuclear magnetic resonance (NMR) spectroscopy
The concentration of extracellular media metabolites was de-
termined by 1H NMR spectroscopy, as previously described (Alves et al.,
2011). For internal reference we used sodium fumarate (singlet at
6.50 ppm) to quantify the following metabolites (multiplet, ppm): H1-
α-glucose (doublet, 5.22), lactate (doublet, 1.33), pyruvate (singlet,
1.35), alanine (doublet, 1.45), acetate (singlet, 1.90). The spectral
analysis was done offline using the NUTSpro™ NMR (Acorn, Fremont,
USA) to quantify the relative areas of 1H NMR resonances by a curve-
fitting routine.
2.14. Statistical analysis
Statistical significance was assessed by one-way ANOVA. All results
were performed in triplicate and data are shown as mean ± SEM
(n=6 for each condition). Statistical analysis was performed using
GraphPad Prism 6 (GraphPad Software, San Diego, CA, USA). P < .05
was considered significant.
3. Results
3.1. GLP-1 receptor is expressed in hSCs
GLP-1R was previously identified in the mice testis, only by im-
munohistochemistry (Zhang et al., 2015). We investigated the presence
of GLP-1R in hSCs and detected a 300 bp amplicon, corresponding to
the presence of GLP-1R mRNA (Fig.1A). Our results also show that,
when exposed to the different concentrations of GLP-1, hSCs do not
present alteration in the transcript levels of GLP-1R (Fig. 1B).
Table 1
Primers used in this study
Gene Primer sequence (5′-3′) AT(°C) Amplicon size
(bp)
GLP-1R Sense: GCTCTCCTTCACCTCCTTCC 58 300
Anti-Sense: TGTCTCTCCCACCTGGATTG
ND1 Sense: CGATTCCGCTACGACCAACT 60 121
Anti-Sense: AGGTTTGAGGGGGAATGCTG
β2M Sense: ATGAGTATGCCTGCCGTGTG 60 150
Anti-sense:
CAAACCTCCATGATGCTGCTTAC
β2Mnc Sense: GAGGCTATCCAGCGTGAGTC 60 306
Anti-sense: GACGCTTATCGACGCCCTAA
Abbreviations: β2M: Beta-2-Microglobulin; β2Mnc: nuclear encoded beta-2-
microglobulin; GLP-1R: Glucagon like peptide-1 receptor; ND1: NADH dehy-
drogenase, subunit 1.
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3.2. Glucose consumption is decreased in hSCs exposed to GLP-1
Glucose is essential for SCs metabolism and spermatogenesis. This
metabolite enters SCs mostly through glucose transporters (GLUTs),
GLUT1–3 (Martins et al., 2015; Martins et al., 2016). After treatment
with GLP-1, no alterations were detected in the protein levels of those
GLUTs in hSCs (Supplementary Fig. 1A to C). Nevertheless, when hSCs
were exposed to 0.01 and 1 nM of GLP-1, glucose consumption de-
creased to 45.35 ± 18.40 and 25.66 ± 15.60 pmol/cell, respectively,
while cells exposed to 100 nM of GLP-1 consumed 75.82 ± 28.40 pmol
of glucose/cell and those not exposed to GLP-1 consumed
122.30 ± 30.70 pmol of glucose/cell (Fig. 2A). SCs also produce
acetate (Alves et al., 2012), which is exported to the intratubular fluid
by monocarboxylate transporters (MCTs), as is lactate. Our results show
that hSCs exposed to all GLP-1 concentrations did not alter the protein
levels of MCT4 (Supplementary Fig.1D). On the other hand, acetate
production by hSCs exposed to 1 nM of GLP-1 increased to
2.49 ± 0.38 pmol/cell when compared to non-exposed cells that pro-
duced 1.34 ± 0.31 pmol/cell of acetate (Supplementary Fig. 2C).
3.3. Exposure to GLP-1 increased lactate production by hSCs
Once inside the cell, glucose is metabolized to pyruvate. Pyruvate is
at a crossroad of several metabolic pathways. Exposure of hSCs to GLP-
1 did not alter the consumption of pyruvate (Supplementary Fig. 2A).
One of the metabolic pathways originated from pyruvate is the con-
version to alanine by alanine aminotransferase. When we evaluated
alanine production by hSCs exposed to GLP-1 no differences were ob-
served (Supplementary Fig. 2B). In these cells, the majority of pyruvate
is converted to lactate by LDH. Our results showed that lactate pro-
duction by hSCs exposed to GLP-1 increased to 11.49 ± 2.06 and
11.49 ± 1.67 pmol/cell for cells exposed to 0.01, 1 nM, respectively,
when compared to non-exposed hSCs (6.72 ± 2.48 pmol/cell of lac-
tate) (Fig. 2B). We further analysed LDH expression and detected that it
slightly decreased in cells exposed to 100 nM of GLP-1 to 0.86 ± 0.03-
fold variation to non-exposed cells when compared to cells exposed to
1 nM of GLP-1 (0.94 ± 0.02-fold variation to non-exposed cells
(Fig. 2C). However, LDH activity was increased in hSCs exposed to
100 nM of GLP-1 to 1.26 ± 0.16-fold variation relative to non-exposed
cells and when compared to hSCs exposed to 1 nM of GLP-1, which,
presented an activity of 0.78 ± 0.11-fold variation relative to non-
exposed cells (Fig. 2D).
3.4. Human SCs exposed to 100 nM of GLP-1 presented decreased
mitochondrial membrane potential
Our data showed that mitochondrial membrane potential decreased
in SCs exposed to 100 nM (ratio of 0.61 ± 0.02), when compared to
non-exposed or those exposed to 0.01 and 1 nM of GLP-1 (ratio of
1 ± 0.06; 1.15 ± 0.07 and 1.11 ± 0.10, respectively) (Fig. 3A). Still,
when we analysed the relative quantity of mitochondrial DNA no al-
teration was observed in hSCs exposed to GPL-1 when compared to non-
exposed cells (Fig. 3B).
3.5. Carbonyl group levels decreased in hSCs exposed to 1 and 100 nM
when compared to 0.01 nM of GLP-1
The high glycolytic flux, followed by the conversion of pyruvate to
lactate, as happens in SCs, enhances a pro-oxidative environment. The
products of protein carbonylation (dinitrophenol (DNP)), nitration (NT)
and lipid peroxidation (4-HNE) are biomarkers for oxidative stress.
Table 2
Antibodies used in this study
Antibody Source Molecular Weight (kDa) Dilution Vendor Catalog #
GLUT1 Rabbit 55 1:500 Santa Cruz Biotechnology, Heidelberg, Germany sc-7903
GLUT2 Rabbit 61 1:5000 Santa Cruz Biotechnology, Heidelberg, Germany sc-9117
GLUT3 Goat 48 1:500 Santa Cruz Biotechnology, Heidelberg, Germany sc-7582
MCT4 Rabbit 43 1:1000 Santa Cruz Biotechnology, Heidelberg, Germany sc-50329
LDH Rabbit 37 1:10000 Abcam, Cambridge, MA, USA ab52488
Catalase Mouse 60 1:4000 Sigma-Aldrich, Roedermark, Germany C0979
P-mTOR Rabbit 289 1:500 Cell Signaling Technology, Danvers, MA, USA 2971S
β-Tubulin Mouse 50 1:5000 Thermo Fisher Scientific, Rockford, USA MA5-16308
DNP Rabbit — 1:5000 Sigma-Aldrich, Roedermark, Germany D9656
4-HNE Goat — 1:5000 EMD Millipore, Temecula, CA, USA AB5605
Nitro-Tirosine Rabbit — 1:2500 Cell Signaling Technology, Danvers, MA, USA 9691S
Mouse Goat — 1:5000 Sigma-Aldrich, Roedermark, Germany A3562
Rabbit Goat — 1:5000 Sigma-Aldrich, Roedermark, Germany A3687
Goat Rabbit — 1:5000 Sigma-Aldrich, Roedermark, Germany A4187
Abbreviations: 4-HNE- 4 Hydroxynonenal; DNP- Dinitrophenol; GLUT1- Glucose transporter 1; GLUT2- Glucose transporter 2; GLUT3- Glucose transporter 3; LDH-
Lactate dehydrogenase; MCT4- Monocarboxylate transporter 4; P-mTOR- Phospho-mTOR
Fig. 1. Identification and effects of exposure to glucagon like peptide-1 (GLP-1)
in its receptor (GLP-1R) in human Sertoli cells. Panel A - Expression of GLP-1R
in cultured human Sertoli cells identified by reverse transcriptase polymerase
chain reaction. Panel B - Expression of mRNA transcript levels of GLP-1R in
human Sertoli cells exposed to increasing concentrations of GLP-1. Panels B
shows pooled data of independent experiments, indicating the mRNA transcript
levels of GLP-1R. hSCs: human Sertoli cells; hH: human heart; Neg: Negative
control; Neg(RT): Negative without reverse transcriptase. Results are expressed
as mean ± SEM (n=6 for each condition).
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Carbonyl group levels did not altered in any of hSCs exposed groups to
GLP-1 when compared with the no GLP-1 group. However, hSCs ex-
posed to 1 and 100 nM of GLP-1 presented lower levels of carbonyl
groups (0.78 ± 0.07 and 0.86 ± 0.05-fold variation to non-exposed
cells (no GLP-1), respectively (Fig. 4A)) when compared with hSCs
exposed to 0.01 nM of GLP-1 (1.10 ± 0.02-fold variation to non-ex-
posed cells (no GLP-1)). Yet, the levels of 4-HNE and NT groups were
not altered in cells exposed to GLP-1 when compared with non-exposed
cells (Fig. 4B and C, respectively). Additionally, we determined the
protein levels of antioxidant enzymes such as catalase and the total/
reduced glutathione ratio. Our results show that cells exposed to all
GLP-1 concentrations did not presented alterations in the protein levels
of catalase or in the total/reduced glutathione ratio when compared
with the levels detected in non-exposed cells (Supplementary Fig. 3A
and 3B, respectively).
Fig. 2. Effects of glucagon like peptide-1 (GLP-1) in glucose metabolism in human Sertoli cells. Glucose consumption (Panel A), lactate production (Panel B),
expression of lactate dehydrogenase (LDH) (Panel C) and LDH activity (Panel D) in human Sertoli cells after exposure to increasing concentrations of GLP-1 are
represented. Panels A and B show pooled data of independent experiments, indicating the glucose consumption and lactate production, respectively. Panels C and D
show pooled data of independent experiments, indicating the protein levels and activity of LDH, respectively. Panels C also show representative Western Blot
experiments. Results are expressed as mean ± SEM (n=6 for each condition). Significantly different results (p < .05) are as indicated: * relative to non-exposed
cells (no GLP-1); § relative to 1 nM.
Fig. 3. Effects of glucagon like peptide-1 (GLP-1) in mitochondria function of human Sertoli cells. JC-1 ratio (Panel A) and mitochondrial relative copies (Panel B) in
human Sertoli cells exposed to increasing concentrations of GLP-1 are represented. Panel A shows JC-1 ratio found in human Sertoli cells cultured with increasing
concentrations of GLP-1 or without GLP-1. Panel B shows pooled data of independent experiments indicating mitochondrial DNA (mtDNA) quantity by quantitative
PCR. Results are expressed as mean ± SEM (n=6 for each condition). Significantly different results (p < .05) are as indicated: * relative to non-exposed cells (no
GLP-1); # relative to 0.01 nM; § relative to 1 nM.
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3.6. Phosphorylated mTOR is increased in hSCs exposed to 100 nM of GLP-
1
mTOR has a crucial role in coordinating cellular homeostasis and
energy status (Chiang and Abraham, 2005). Recent studies demonstrate
that mTOR signalling modulates the glycolytic and oxidative profile in
hSCs (Jesus et al., 2016). GLP-1 had no effects regarding mTOR phos-
phorylation in hSCs of any of the exposed groups when compared with
expression in hSCs of no GLP-1 group. Still, hSCs exposed to 100 nM of
GLP-1 presented an increase in the protein levels of phosphorylated
mTOR (Ser2448), to 1.41 ± 0.28-fold variation to non-exposed cells
(no GLP-1) when compared to hSCs exposed to 0.1 nM of GLP-1
(0.77 ± 0.12-fold variation relative non-exposed cells (no GLP-1))
(Fig. 5).
4. Discussion
GLP-1 is a peptide hormone with an active role in the regulation of
circulating glucose levels (Brubaker, 2006). Glucose equilibrium is
crucial for energy homeostasis and the proper functioning of
physiological functions, including male fertility (Dunning et al., 2005).
Excessive fat accumulation is associated with dysregulation of energy
homeostasis signalling systems, and with a concurrent impairment of
GLP-1 mediated functions (Dirksen et al., 2013). Several GLP-1 analo-
gues are now used as pharmacological agents to promote weight loss
(Blundell et al., 2017). Recent studies have consistently associated the
increase in obesity rates with decreased male fertility (Rato et al.,
2014a). In 2030, it is estimated that over 50% of the world population
will be overweight/obese (Smith and Smith, 2016), which will ag-
gravate male infertility trends. Alterations in SC metabolism were hy-
pothesized to contribute for reduced fertility in obese males (Winters
et al., 2006). In fact, the SCs are responsible for the nutritional support
of spermatogenesis.
There is evidence that GLP-1 may influence male reproductive
function (Jeibmann et al., 2005), although few studies have been fo-
cused on the molecular mechanisms. Since SCs are major hormonal
targets within the testis (Alves et al., 2014; Martins et al., 2015; Martins
et al., 2016), we hypothesized that GLP-1 could directly modulate the
metabolic functions of these cells and has a possible effect on male
fertility. For that, we exposed hSCs to increasing doses of GLP-1 to
evaluate: (1) the impact of the postprandial levels of GLP-1; (2) the
impact of GLP-1 when present at the levels reached by its analogues
(liraglutide) in the plasma of healthy/obese individuals. The maximum
plasma concentrations found in overweight and obese subjects treated
with GLP-1 analogues is similar to the one observed in healthy in-
dividuals (Onge et al., 2016). GLP-1 actions are mediated by the GLP-
1R. So far GLP-1R has only been identified in mice SCs by im-
munohistochemistry of the testicular tissue (Zhang et al., 2015). Our
results allowed us to observe for the first time the expression of GLP-1R
in isolated hSCs. Interestingly, GLP-1 exposure did not change GLP-1R
expression in cultured hSCs, illustrating that the mRNA expression of
this receptor in these cells is not rapidly responsive to exposure to in-
creasing GLP-1 concentrations.
We then evaluated the impact of GLP-1 postprandial levels in hSCs
metabolism and bioenergetics. These cells uptake glucose from the in-
terstitial fluid by the action of GLUTs (GLUT1–3). Glucose is then used
to produce essential metabolites (mainly lactate) that will serve as en-
ergy sources for developing germ cells (Martins et al., 2015; Martins
et al., 2016). Although GLP-1 exposure did not alter GLUTs expression,
hSCs decreased the consumption of glucose after exposure to post-
prandial levels of this hormone, as compared to non-exposed cells.
Concurrent results had been reported in other mammalian cell lines,
with GLP-1 exposure decreasing deoxyglucose uptake (Morales et al.,
2014). Our results suggest that this hormone is capable of eliciting an
alteration of glucose uptake, likely due to an alteration on its
Fig. 4. Detection of oxidative damage in human Sertoli cells exposed to increasing concentrations of glucagon like peptide-1 (GLP-1). The levels of carbonyl (Panel
A), 4-hydroxynonenal (4-HNE) (Panel B) and nitro-tyrosine (NT) (Panel C) groups after exposure of human Sertoli cells to increasing concentrations of GLP-1 are
represented. Panels A to C show pooled data of independent experiments, indicating the expression levels of carbonyl, 4-HNE and NT, respectively. Panels A-C also
show representative Slot blot experiments. Results are expressed as mean ± SEM (n=6 for each condition). Significantly different results (p < .05) are as in-
dicated: # relative to 0.01 nM.
Fig. 5. Effect of glucagon like peptide-1 (GLP-1) on mammalian target of ra-
pamycin (mTOR) signalling pathway. The protein expression levels of phos-
phorylated mTOR (Ser2448) in human Sertoli cells after exposure to increasing
concentrations of GLP-1 are represented. Figure shows pooled data of in-
dependent experiments, indicating the expression levels of P-mTOR. Figure also
show representative Western Blot experiments. Results are expressed as
mean ± SEM (n=6 for each condition). Significantly different results
(p < .05) are as indicated: # relative to 0.01 nM.
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metabolism. Still, GLP-1 postprandial levels were capable to stimulate
lactate production by hSCs. Previous studies, show that lactate is es-
sential for spermatogenesis (Oliveira et al., 2011) since it is used as
metabolic fuel by developing germ cells (Boussouar and Benahmed,
2004) and has an anti-apoptotic effect on those cells (Rato et al.,
2014b). The postprandial levels of GLP-1 increased the production of
lactate, while glucose consumption was decreased, as compared to non-
exposed cells, illustrating the metabolic commitment of these cells to an
efficient production of lactate. No effect was detected on mitochondria
functionality in these cells. Neither mitochondrial membrane potential
nor DNA content were affected by exposure to these levels of GLP-1.
Moreover, the oxidative stress markers (protein carbonyl and nitro-
tyrosine groups, and lipid peroxides) were not altered, which correlates
with a normal functioning of the mitochondria. Hence, at postprandial
levels, GLP-1 seems to be vital for eliciting the production of lactate by
hSCs, which in turn consume lower amounts of glucose. These cells
have adaptive mechanisms, and show a metabolic plasticity (Alves
et al., 2014; Martins et al., 2015; Martins et al., 2016; Meneses et al.,
2016) that is very important to sustain the metabolic support of sper-
matogenesis. They utilize a wide sort of metabolic sources to produce
lactate, namely from triglycerides that accumulate as lipid droplets
(Gorga et al., 2017). Depending on the substrate availability and on
stimuli, SCs can oxidize these cytoplasmic lipidic droplets to support
their metabolic requirements (Jutte et al., 1985). It has been described
that GLP-1 may promote lipid droplet remodelling and lipolysis in
human adipocytes, when present at concentrations above 10−11 M
(Villanueva-Penacarrillo et al., 2001). A similar event may be occurring
in hSCs exposed to the postprandial levels of GLP-1 (Vilsboll et al.,
2001; Balestrieri et al., 2015).
Similar results were obtained when the hSCs were exposed to GLP-1
concentrations that mimic the levels of GLP-1 analogues observed in the
plasma after a single administration of liraglutide at the therapeutic
dosage recommended for obese individuals (Elbrond et al., 2002). Both
glucose consumption and lactate production were maintained, when
compared to cells exposed to postprandial levels of GLP-1. The SC is
responsible for producing lactate favouring the glycolytic flux (Oliveira
et al., 2015), but it also uses mitochondrial oxidative phosphorylation
to sustain its own energetic needs. Human SC exposed to 1 nM of GLP-1
presented an increase in acetate production, however this did not lead
to an increase in mitochondrial membrane potential, as observed in
other cell lines (Morales et al., 2014). No changes were observed in the
pro-oxidant environment, nitration and lipid peroxidation, nor in the
levels of antioxidant defences, but we found less oxidative damage in
proteins of cells exposed to this concentration of GLP-1. This protective
effect mediated by GLP-1 may be essential to counteract the pro-oxidant
environment promoted by an increased metabolic activity.
Contrasting results were obtained with cells exposed to GLP-1
concentrations that mimic the levels of GLP-1 analogues observed in the
plasma after a prolonged administration of liraglutide at the therapeutic
dosage recommended for obese individuals (Jiang et al., 2011; Danne
et al., 2017). In this case, hSCs appear to consume higher amounts of
glucose, producing the same amounts of lactate, as compared to cells
exposed to postprandial GLP-1 levels. This increased glucose con-
sumption was associated with LDH activity stimulation, which suggest
an adaptation to sustain lactate production. In fact, hSCs exposed to
100 nM of GLP-1, presented a decrease in mitochondrial membrane
potential. As said, SCs have a distinct metabolic behaviour when
compared to most somatic cells, with remarkable metabolic resem-
blances with cancer cells (Oliveira et al., 2015). Thus, decreased mi-
tochondrial membrane potential may not be a sign of compromised
function, but rather a shift to sustain the metabolic biosynthetic re-
quirements of developing germ cells and redirecting the metabolism of
the cell for oxidative phosphorylation. Indeed, when we accessed oxi-
dative damage, which is often associated with mitochondria malfunc-
tion, the exposure to 100 nM GPL-1 did not promote protein nitration
nor lipid peroxidation, but these cells rather showed less oxidative
damage in proteins without any changes in the levels of antioxidant
defences. Again, GLP-1 appears to exert a protective effect that is es-
sential to counteract testicular pro-oxidant environment. Although
these results suggest that GLP-1 has an antioxidant effect the exact
mechanism by which GLP-1 decreases oxidative stress in hSCs remains
to be elucidated. Our studies further suggest that these alterations in
glucose metabolism and mitochondrial function in hSCs exposed to
100 nM GPL-1 are associated with stimulation of mTOR Complex 1
(mTORC1) pathway, as mTOR phosphorylation at Ser2448 is increased.
Although the significance of mTORC1 pathway for GLP-1 mediated
effects is unclear, the involvement of this signalling pathway has been
described in several cellular systems (Ravassa et al., 2011).
In conclusion, GLP-1 was able to modulate glucose metabolism and
bioenergetics, promoting the production of lactate by hSCs. Moreover,
exposure to the highest concentration of GLP-1 decreased oxidative
damage in these cells. Also, the absence of toxic effects of GLP-1 at this
concentration in hSCs, allied to a decrease in oxidative damage, adds a
possible positive impact on male fertility. Still, further experiments are
needed to clarify the effects of GLP-1 in male reproductive health and to
determine if the effects observed in vitro translate to in vivo. Taking in
consideration the decline of fertility rates parallel to the increasing
prevalence of obesity, it is crucial to understand how GLP-1 affects male
fertility. The use of GLP-1 analogues for obesity treatment could also be
valuable to counteract the negative impact of adiposity related meta-
bolic dysregulation in male reproductive function and arise as an ad-
ditional target for medical intervention.
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